Phost’in Therapeutics Is Awarded €3.2m Through The France 2030 Investment Plan To Pioneer N-Glycosylation Inhibitors Against Chronic Fibrosis
Montpellier, France – August 2023, 25th
Lire la suite
Phost’in Therapeutics and the Gianni Bonadonna Foundation Announce Opening of 2 Expansion Cohorts in the PhAST Trial
Montpellier, France – August 2023, 25th
Taiho Pharmaceutical and Phost’in Therapeutics announce an Option and License Agreement on the First-in-Class GnT-V inhibitor PhOx430
Montpellier, France – August 2023, 25th
Phost’in Therapeutics joins TechShare 2022, Euronext’s paneuropean Pre-IPO training program
Montpellier, France – Mars 2022, 09th
Phost’in Therapeutics strengthens management with appointment of veteran lifescience executives Dr. Alain Herrera and Pr. Bernard Pau
Montpellier, France – June 2020, 17th
Phost’in Therapeutics raises €10.3m to develop First-in-Class N-glycosylation Inhibitors for Cancer Treatment
Montpellier, France – April 2020, 20th